로딩 중…
지수 로딩 중…
MoonLake Immunotherapeutics
MLTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
CH
CH$17.40-5.64%
2026-08-03
Financials
Valuation Metrics
MoonLake Immunotherapeutics's Market Cap is $1.28B. At end of 2025 it was $850M. Ranked #2338 of 3,112 in US market (top 75%), #934 of 1,445 on NASDAQ (top 65%), #173 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.28B | US#2,338/3,112 Sec#173/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-257M | US—/3,112 Sec—/269 |
| Total Assets | $400M | US#2,830/3,112 Sec#186/269 |
| Net Assets | $254M | US#2,633/3,112 Sec#175/269 |
| Value | ||
| P/B | 5.04x | US#2,185/3,112 Sec#141/269 |
| FCF Yield | -17.50% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -101.20% | US#2,851/3,112 Sec#220/269 |
| ROA | -64.21% | US#3,014/3,112 Sec#244/269 |
| Financial Health | ||
| Debt Ratio | 57.61% | US#643/3,112 Sec#146/269 |
| Total Debt | $101M | US#2,385/3,112 Sec#116/269 |
| FCF | $-224M | US#2,746/3,112 Sec#224/269 |
| Cash | $298M | US#1,430/3,112 Sec#80/269 |
| Current Ratio | 8.60x | US#290/3,112 Sec#94/269 |
| Performance | ||
| 1Y Return | -67.12% | US#3,074/3,112 Sec#261/269 |
| 1M Return | -8.18% | US#2,494/3,112 Sec#149/269 |
| From 52W High | -72.27% | US#3,038/3,112 Sec#255/269 |
| 1Y MDD | -89.92% | US#3,107/3,112 Sec#268/269 |
| Trading | ||
| Volume | 1,240,856 shares | US#1,301/3,112 Sec#129/269 |
| Trading Value | $22M | US#1,906/3,112 Sec#139/269 |
| Per Share | ||
| EPS | $-3.53 | US—/3,112 Sec—/269 |
| BPS | $4.72 | US#2,252/3,112 Sec#136/269 |